Michel Sadelain, MD, PhD
Director, Center for Cell Engineering &
Gene Transfer and Gene Expression
Memorial Sloan-Kettering Cancer Center
Dr. Michel Sadelain is Professor and Director, Center for Cell Engineering at Memorial Sloan Kettering Cancer Center. He completed his MD at The University of Paris in 1984 and his PhD in Immunology at the University of Alberta in 1989. Since 2007, he has held the position of Director at the Center for Cell Engineering at Memorial Sloan Kettering Cancer Center. His clinical focus is the mechanisms governing transgene expression, stem cell engineering, and genetic strategies to enhance immunity against cancer. The advent of technologies that permit efficient gene transfer in human primary cells reates novel therapeutic perspectives. Based on the use of recombinant oncoretroviruses and lentiviruses, we are investigating how to control transgene expression in vivo in hematopoietic stem cells and how to augment immune responses against tumor cells. Our current studies on the first topic focus on the role of locus control regions and insulators in regulating the transcription of randomly integrated beta globin transgenes. With respect to tumor immunity, we are exploring different strategies to target T cells to tumor cells, either by facilitating dendritic cell-T cell interactions or by enhancing the co-stimulation of T cells that engage tumor cells.